1. Home
  2. CUE vs EURK Comparison

CUE vs EURK Comparison

Compare CUE & EURK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CUE
  • EURK
  • Stock Information
  • Founded
  • CUE 2014
  • EURK 2023
  • Country
  • CUE United States
  • EURK Hong Kong
  • Employees
  • CUE N/A
  • EURK N/A
  • Industry
  • CUE Biotechnology: Pharmaceutical Preparations
  • EURK
  • Sector
  • CUE Health Care
  • EURK
  • Exchange
  • CUE Nasdaq
  • EURK NYSE
  • Market Cap
  • CUE 77.3M
  • EURK 80.0M
  • IPO Year
  • CUE 2018
  • EURK 2024
  • Fundamental
  • Price
  • CUE $1.31
  • EURK $10.17
  • Analyst Decision
  • CUE Strong Buy
  • EURK
  • Analyst Count
  • CUE 5
  • EURK 0
  • Target Price
  • CUE $5.00
  • EURK N/A
  • AVG Volume (30 Days)
  • CUE 406.9K
  • EURK 19.6K
  • Earning Date
  • CUE 03-10-2025
  • EURK 01-01-0001
  • Dividend Yield
  • CUE N/A
  • EURK N/A
  • EPS Growth
  • CUE N/A
  • EURK N/A
  • EPS
  • CUE N/A
  • EURK 0.18
  • Revenue
  • CUE $9,532,000.00
  • EURK N/A
  • Revenue This Year
  • CUE $73.11
  • EURK N/A
  • Revenue Next Year
  • CUE $11.02
  • EURK N/A
  • P/E Ratio
  • CUE N/A
  • EURK $55.20
  • Revenue Growth
  • CUE 149.53
  • EURK N/A
  • 52 Week Low
  • CUE $0.45
  • EURK $10.03
  • 52 Week High
  • CUE $2.93
  • EURK $10.18
  • Technical
  • Relative Strength Index (RSI)
  • CUE 52.47
  • EURK N/A
  • Support Level
  • CUE $1.21
  • EURK N/A
  • Resistance Level
  • CUE $1.75
  • EURK N/A
  • Average True Range (ATR)
  • CUE 0.18
  • EURK 0.00
  • MACD
  • CUE 0.00
  • EURK 0.00
  • Stochastic Oscillator
  • CUE 45.00
  • EURK 0.00

About CUE Cue Biopharma Inc.

Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others.

About EURK EUREKA ACQUISITION CORP

Eureka Acquisition Corp is a newly incorporated blank check company.

Share on Social Networks: